On May 2, 2021 Sengenics, the Functional Proteomics Company, reported the commercial launch of the Sengenics AxCESS research services suite which features three new KREX-based functional protein arrays developed for higher throughput and cost-effective immuno-proteomics applications (Press release, Sengenics, MAR 2, 2021, View Source [SID1234575969]). This range of arrays aims to provide greater access to Sengenics’ KREX technology to further facilitate autoantibody characterisation with a focus on autoimmune and cancer research.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The presence of autoantibodies years before disease onset makes them important potential biomarkers for early diagnosis and better prognosis. However, the field of autoantibody-based immuno-proteomics has been under researched to date and has been restricted by the availability of technologies that have the reproducibility, dynamic range, low limit of detection and low false positive rates required for autoantibody biomarker discovery. With KREX, higher sensitivity and accuracy is achieved due to the production of full-length, correctly folded proteins and our unique surface chemistry. I am delighted that we are now able to make this technology more widely accessible and affordable to researchers who are working towards making impactful contributions in this field," said Professor Jonathan Blackburn, CSO of Sengenics.
In the last 12 months, Sengenics has made significant discoveries of highly accurate autoantibody biomarker signatures for early diagnosis of Melanoma, Systemic Lupus Erythematosus and illness severity in COVID-19. In addition, the company has filed landmark patents for response prediction in one of the world’s best-selling autoimmune drugs and early diagnosis of Non-small Cell Lung Cancer. Sengenics has also developed the OncoREX p53 cancer array in collaboration with Professor Sir David Lane. Containing over 100 clinically relevant mutant p53 variants, OncoREX can be used for drug discovery as well as autoantibody and antibody screening in cancers.
In conjunction with the launch of AxCESS, Sengenics has made significant investments in scaling up production and operations to provide faster turnaround times and enhanced service offerings.